With artificial intelligence, a new chapter of modern drug discovery has begun. This novel technology is making everything faster and smart in drug discovery and development processes.
The pharmaceutical industry is also noticing the deep impact of artificial intelligence. Wondering how much confidence there is in AI tools? According to Coherent Market Insights, the global artificial intelligence in drug discovery industry touched a mark of US$ 1016.1 million in 2022 and is set to expand at 5.7% CAGR during the forecast period. By 2030, the global industry valuation is projected to grow 3.5X, reaching US$ 3547.4 million.
Having AI tools is like having thousands of scientists working continuously for exploring promising treatments that humans might miss. However, choosing a right AI tool can be tricky as well as a laborious task. To make this easy, lets discuss some of the top AI tools that are making strides in drug discovery processes.
Exscientia
Exscientia tops our list of the best AI tools for drug discovery. It is changing the way new medicines are developed for complicated diseases. In fact, Exscientia was the first company to successfully translate AI-designed small molecules into clinical trials. This demonstrates its leadership in applying artificial intelligence to drug discovery.
Exscientis uses AI-powered drug design to speed up the discovery process by combining protein structure, protein targets, robotic automation, and machine learning. This gives them the flexibility to find and optimize drug candidates much faster than traditional methods. It leverages AI and other advanced technologies to create more effective medicines for patients faster.
AlphaFold
Developed by DeepMind, AlphaFold has gained global attention for its groundbreaking ability to predict protein structures with remarkable efficiency. This artificial intelligence program utilizes deep learning to predict 3D structures of proteins. This capability of AlphaFold accelerates the understanding of how proteins function and interact with potential drugs, enabling more precise drug design.
AlphaFold software has three versions, the latest being AlphaFold 3. This advanced deep learning system (AlphaFold 3) was released in May 2024. It has the tendency to predict structures of complexes created by proteins with RNA, DNA, ions, and ligands. Compared to traditional models, AlphaFold shows a minimum 50% improvement in accuracy for protein interactions with other molecules.
AlphaFold is a perfect solution for pharmaceutical companies for rapid drug design and development. It has the potential to predict protein structures accurately, thereby making way for AI-driven precision medicine approaches.
Atomwise
Atomwise leads from the forefront when it comes to AI drug discovery. It utilizes the power of AI and machine learning to revolutionize small molecule drug discovery. The company’s proprietary AI technology, AtomNet, can analyze over 100 million compounds each day. As a result, it helps researchers identify potential drug candidates much faster than traditional drug discovery methods.
Atomwise is transforming the way pharmaceutical research is done. It offers benefits like rapid compound screening capabilities and high accuracy in prediction. These capabilities are useful in the early stages of drug discovery and help researchers focus on the most promising drug candidates.
BenevolentAI
BenevolentAI is another powerhouse in AI drug discovery domain that operates in the United States and the United Kingdom. It leverages artificial intelligence to develop new medicines for the treatment of various diseases.
BenevolentAI’s platform enables researchers to design and develop novel treatments using a large amount of extracted and deduced biomedical information. It combines smart screening technology with a massive database that analyzes millions of clinical data points and scientific papers.
What makes BenevolentAI’s platform so special? The answer is its ability to cut the typical drug development time and reduce overall costs. It uses AI and ML to streamline the drug discovery process. BenevolentAI has already partnered with major pharmaceutical companies and has several promising treatments in clinical trials for individual patients.
